CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo

Isabelle Hubeek; E. M. Comijn; C. L. Van der Wilt; R. L. Merriman; J. M. Padron; G. J.L. Kaspers; G. J. Peters

CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo

Isabelle Hubeek, E. M. Comijn, C. L. Van der Wilt, R. L. Merriman, J. M. Padron, G. J.L. Kaspers, G. J. Peters

Research output: Contribution to journal › Article › peer-review

24 Citations (Scopus)

Abstract

N-acetyl-dinaline (CI-994) is an investigational anti-cancer drug which inhibits histone deacetylases. We evaluated the interaction between CI-994 and conventional chemotherapeutics used in acute myeloid leukemia (AML) in a rat model for AML and Brown Norway rat acute myelocytic leukemia (BNML). In vitro, CI-994 in combination with cytarabine (ara-C), daunorubicin and mitoxantrone, resulted in moderate synergism. In vivo, higher dosages of CI-994 induced complete remissions. CI-994/ ara-C was very active against BNML. The combinations of CI-994/ daunorubicin and CI-994/mitoxantrone were also active against BNML. This study demonstrates favorable in vitro and in vivo interactions between CI-994 and conventional anti-cancer agents used for the treatment of AML.

Original language	English
Pages (from-to)	1517-1523
Number of pages	7
Journal	Oncology Reports
Volume	19
Issue number	6
Publication status	Published - Jun 2008
Externally published	Yes

Keywords

Acute myeloid leukemia
Cytarabine
Histone deacetylase inhibitors
N-acetyl-dinaline

Cite this

@article{49b175b335374f32bfaf14a4dda51a85,

title = "CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo",

abstract = "N-acetyl-dinaline (CI-994) is an investigational anti-cancer drug which inhibits histone deacetylases. We evaluated the interaction between CI-994 and conventional chemotherapeutics used in acute myeloid leukemia (AML) in a rat model for AML and Brown Norway rat acute myelocytic leukemia (BNML). In vitro, CI-994 in combination with cytarabine (ara-C), daunorubicin and mitoxantrone, resulted in moderate synergism. In vivo, higher dosages of CI-994 induced complete remissions. CI-994/ ara-C was very active against BNML. The combinations of CI-994/ daunorubicin and CI-994/mitoxantrone were also active against BNML. This study demonstrates favorable in vitro and in vivo interactions between CI-994 and conventional anti-cancer agents used for the treatment of AML.",

keywords = "Acute myeloid leukemia, Cytarabine, Histone deacetylase inhibitors, N-acetyl-dinaline",

author = "Isabelle Hubeek and Comijn, {E. M.} and {Van der Wilt}, {C. L.} and Merriman, {R. L.} and Padron, {J. M.} and Kaspers, {G. J.L.} and Peters, {G. J.}",

year = "2008",

month = jun,

language = "English",

volume = "19",

pages = "1517--1523",

journal = "Oncology Reports",

issn = "1021-335X",

publisher = "Spandidos Publications",

number = "6",

}

TY - JOUR

T1 - CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo

AU - Hubeek, Isabelle

AU - Comijn, E. M.

AU - Van der Wilt, C. L.

AU - Merriman, R. L.

AU - Padron, J. M.

AU - Kaspers, G. J.L.

AU - Peters, G. J.

PY - 2008/6

Y1 - 2008/6

N2 - N-acetyl-dinaline (CI-994) is an investigational anti-cancer drug which inhibits histone deacetylases. We evaluated the interaction between CI-994 and conventional chemotherapeutics used in acute myeloid leukemia (AML) in a rat model for AML and Brown Norway rat acute myelocytic leukemia (BNML). In vitro, CI-994 in combination with cytarabine (ara-C), daunorubicin and mitoxantrone, resulted in moderate synergism. In vivo, higher dosages of CI-994 induced complete remissions. CI-994/ ara-C was very active against BNML. The combinations of CI-994/ daunorubicin and CI-994/mitoxantrone were also active against BNML. This study demonstrates favorable in vitro and in vivo interactions between CI-994 and conventional anti-cancer agents used for the treatment of AML.

AB - N-acetyl-dinaline (CI-994) is an investigational anti-cancer drug which inhibits histone deacetylases. We evaluated the interaction between CI-994 and conventional chemotherapeutics used in acute myeloid leukemia (AML) in a rat model for AML and Brown Norway rat acute myelocytic leukemia (BNML). In vitro, CI-994 in combination with cytarabine (ara-C), daunorubicin and mitoxantrone, resulted in moderate synergism. In vivo, higher dosages of CI-994 induced complete remissions. CI-994/ ara-C was very active against BNML. The combinations of CI-994/ daunorubicin and CI-994/mitoxantrone were also active against BNML. This study demonstrates favorable in vitro and in vivo interactions between CI-994 and conventional anti-cancer agents used for the treatment of AML.

KW - Acute myeloid leukemia

KW - Cytarabine

KW - Histone deacetylase inhibitors

KW - N-acetyl-dinaline

UR - http://www.scopus.com/inward/record.url?scp=48849094081&partnerID=8YFLogxK

M3 - Article

C2 - 18497959

AN - SCOPUS:48849094081

SN - 1021-335X

VL - 19

SP - 1517

EP - 1523

JO - Oncology Reports

JF - Oncology Reports

IS - 6

ER -

CI-994 (N-acetyl-dinaline) in combination with conventional anti-cancer agents is effective against acute myeloid leukemia in vitro and in vivo

Abstract

Keywords

Fingerprint

Cite this